| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,280,000 |
| Market
Cap: |
106.35(M) |
| Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,771 |
| 52
Week Range: |
$2.25 - $7.96 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.6 |
| Insider 6 Months : 14.8 |
| Insider 3/6 Months : 23.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53,764 |
357,764 |
382,819 |
550,734 |
| Total Buy Value |
$200,002 |
$981,272 |
$1,081,809 |
$1,702,202 |
| Total People Bought |
2 |
6 |
8 |
9 |
| Total Buy Transactions |
2 |
8 |
10 |
16 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hobbs Eamonn P |
President and CEO |
• • – |
2012-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
155,000 |
|
- |
|
| Keck Barbra |
Vice President, Controller |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,800 |
5,800 |
|
- |
|
| Miao Graham G |
Exec. V.P., CFO |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
34,000 |
|
- |
|
| Purpura John |
EVP Reg. Affairs/Quality Assur |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
15,000 |
|
- |
|
| Mapes Harold |
Exec. V. P., Global Operations |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
17,000 |
|
- |
|
| Graham Peter J |
EVP; General Counsel |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
15,000 |
|
- |
|
| Gago Agustin V |
EVP Global Sales & Marketing |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
80,944 |
|
- |
|
| Kandarpa Krishna |
Exec. V.P., Chief Medical Off. |
• – – |
2012-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
159,000 |
|
- |
|
| Kandarpa Krishna |
Exec. V.P., Chief Medical Off. |
• – – |
2012-01-06 |
4 |
AS |
$3.75 |
$129,790 |
D/D |
(34,606) |
150,000 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-23 |
4 |
AS |
$2.47 |
$24,660 |
I/I |
(10,000) |
631,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-22 |
4 |
AS |
$2.44 |
$24,421 |
I/I |
(10,000) |
641,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-21 |
4 |
AS |
$2.00 |
$20,000 |
I/I |
(10,000) |
651,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-20 |
4 |
AS |
$1.95 |
$19,500 |
I/I |
(10,000) |
661,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-19 |
4 |
AS |
$1.92 |
$19,185 |
I/I |
(10,000) |
671,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-16 |
4 |
AS |
$1.96 |
$19,614 |
I/I |
(10,000) |
681,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-15 |
4 |
AS |
$2.01 |
$20,114 |
I/I |
(10,000) |
691,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-14 |
4 |
AS |
$2.09 |
$20,900 |
I/I |
(10,000) |
701,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-13 |
4 |
AS |
$2.28 |
$22,800 |
I/I |
(10,000) |
711,294 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-12-12 |
4 |
AS |
$2.30 |
$23,000 |
I/I |
(10,000) |
721,294 |
|
- |
|
| Miao Graham G |
Exec. V.P., CFO |
• – – |
2011-09-26 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
| Watson Douglas G |
Director |
– • – |
2011-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,347 |
11,369 |
|
- |
|
| Leung Gabriel |
Director |
– • – |
2011-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,347 |
8,347 |
|
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2011-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,347 |
51,854 |
|
- |
|
| Philips Laura A |
Director |
– • – |
2011-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,347 |
65,854 |
|
- |
|
| Ladd Robert |
Director |
– • – |
2011-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,347 |
36,854 |
|
- |
|
370 Records found
|
|
Page 7 of 15 |
|
|
0.23 (3.2%) 
